Walgreens

Morgan Stanley is out with its report today on Walgreens (NYSE: WAG), maintaining Overweight. In a note to clients, Morgan Stanley writes, "Gross margins could be soft in the near-term, but we know gross margin dollars will be expanding starting in December as the new generics arrive, so we are...

According to a recent report, Goldman Sachs has removed Walgreen (NYSE: WAG) from America's Conviction List but still maintain a Buy rating and a $48.00 price target on the company. In the report, Goldman Sachs said, "We trim our August quarter forecast from Street-high, and now stand at Street...

In a report published by Morgan Stanley, Walgreens (NYSE: WAG) cost control and 2012 generics thesis is intact. Morgan Stanley said that it views today's 7% WAG selloff as a buying opportunity. “Walgreens delivered a slightly better than expected 2Q, but we believe investors were anticipating...

Morgan Stanley reports positive estimates for Walgreens' (NYSE: WAG) second quarter. According to Morgan Stanley, "Earnings on March 22: After meaningful earnings beats in the last 2 quarters, we again see upside to consensus estimates for F2Q as the company's cost control efforts combine with the...